摘要
目的:观察GM1治疗急性脑梗死的临床疗效及安全性。方法:选择96例发病72h内的急性脑梗死患者,随机分为两组,采用中国卒中程度评分(Chinesestrokescale,CSS)、Barthel指数及Rankin残疾评分评价神经功能恢复状况。结果:治疗组显效率52·08%,有效率31·25%;对照组显效率25·00%,有效率52·08%。治疗组Barthel指数变化较对照组明显(P<0·05)。Rankin指数(3个月后)治疗组明显小于对照组,无不良反应发生。结论:GM1治疗急性脑梗死是安全、有效的。
Aim： To evaluate the clinical curative effect and safety of ganglioside GM1 in treatment of acute cerebral infarctions. Methods： 96 patients from the onset within 72 h were randomly divided into two groups： the ganglioside GMI treated group and control group. The Chinese Stroke Scale （CSS）, Barthel Index （BI） , and Rankin Scale were used to evaluate the recovery of neurological functions. Results：The obvious effective rote of the therapy group was 52.08 %, response rate was 31.25% . Whereas, these data of the control group were 25.00% and 52.08%, respectively.The Barthel Index significantly changed in treatment group （ P 〈 0.05） . Rankin Scale at 3 months after initiation significantly decreased in treatment group. Conclusion： Ganglioside GM1 is effective and relative safety in treatment of acute cerebral infarctions.
出处
《中国临床神经科学》
2005年第3期292-293,297,共3页
Chinese Journal of Clinical Neurosciences
